Pediatric Patients With Solid or Hematological Tumor Disease: Vancomycin Population Pharmacokinetics and Dosage Optimization.

Romain Guilhaumou (1) , Amelie Marsot (1) , Julien Dupouey (1) , Claire Galambrun (2) , Audrey Boulamery (3, 4) , Carole Coze (5) , Nicolas Simon (6, 3) , Nicolas G André (7)

1 Service de Pharmacologie Clinique [Hôpital de la Timone - APHM]
2 Service d'Hématologie pédiatrique, Hôpital de la Timone, Marseille
3 Hôpitaux Sud - Hôpital Sainte-Marguerite [CHU - APHM]
4 INP - Institut de neurophysiopathologie
5 Pédiatrie et oncologie pédiatrique [Hôpital de la Timone - APHM]
6 SESSTIM - U912 INSERM - Aix Marseille Univ - IRD - Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale
7 Metronomics Global Health Initiative

In pediatric cancer patients, determination of optimal vancomycin dosage is essential because of high risk of inadequate concentrations and bacterial resistance. The aim of this study was to determine vancomycin pharmacokinetic parameters in this population and propose dosage optimization to achieve optimal concentration.

Domains: Human health and pathology; Cancer; Infectious diseases; Applications [stat.AP]; Pediatrics

Romain Guilhaumou, Amelie Marsot, Julien Dupouey, Claire Galambrun, Audrey Boulamery, et al.. Pediatric Patients With Solid or Hematological Tumor Disease: Vancomycin Population Pharmacokinetics and Dosage Optimization.. Therapeutic Drug Monitoring, 2016, 38 (5), pp.559 - 566. ⟨10.1097/FTD.0000000000000318⟩. ⟨hal-01776345⟩